We represented Altaris, an investment firm exclusively focused on acquiring and building companies in the healthcare industry, in its definitive agreement to acquire Simulations Plus (Nasdaq: SLP), a global leader in model-informed and AI-accelerated drug development, for $18.50 per share in an-all cash transaction valued at approximately $375 million. Upon closing, Simulations Plus (Nasdaq: SLP) will become privately held and will be delisted from the Nasdaq Global Select Market. In connection with the closing, Altaris anticipates Simulations Plus will be combined with Chemical Computing Group, an existing Altaris portfolio company, creating a broader biosimulation platform for drug discovery and development.
The transaction and subsequent combination is expected to close in the second half of 2026, subject to customary regulatory, shareholder, and other similar approvals and closing conditions.
The team was led by Ryan Thomas, Scott Bell, and Tyler Huseman and included corporate attorneys Toyin Edogun, Justin Hay and Michael Muszik; employee benefits attorneys Curtis Fisher and William Gebo; intellectual property attorney Emily Snyder; labor and employment attorney Brittany Roberts; litigation attorneys Luke Smith and Ashleigh Karnell; and debt finance attorney Christina Godard.
“Bass, Berry & Sims is pleased to represent Altaris in its definitive agreement to take Simulations Plus private, a transaction that reflects our continued work advising leading private equity firms on strategic public-to-private acquisitions,” said Ryan Thomas.
The transaction was highlighted in several media outlets, including:
- “Altaris to Acquire Health Tech Firm Simulations Plus in $375M Take-Private Deal,” PE Hub (June 17, 2026)
- “Simulations Plus to Be Acquired by Altaris for Approximately $375 Million,” BioSpace (June 16, 2026)
- “Simulations Plus to Be Acquired by Altaris for Approximately $375 Million,” Yahoo Finance (June 16, 2026)